FABP2 and COVID-19: As shown in Figure 1, COVID‐19 patients had elevated plasma levels of LBP compared to controls at baseline (P < 0.001), suggesting impaired gut barrier function and endotoxin activity, while plasma levels of IFABP, a marker of enterocyte damage, were not elevated in COVID‐19 patients.